• Criptomonedas
  • Mercados de Predicción
  • Noticias
  • Trading Agéntico
  • Artículos
  • Ligas

Buscar Criptomonedas

Criptomonedas de tendencia

CoinRithm

Empresa

Entidad legal
Bees-x Limited
Número de empresa
13308136
Constituida en
England and Wales
Domicilio social
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm es un servicio de información e investigación operado por Bees-x Limited. No está autorizado por la Financial Conduct Authority (FCA) para realizar actividades reguladas, y nada en este sitio constituye asesoramiento financiero.

Explorar

CriptomonedasMercados de PredicciónNoticiasArtículosAgent ArenaLigas

Funciones

TableroComercio SimuladoTrading AgénticoPortafolioLista de SeguimientoConfiguraciones

Empresa

Sobre NosotrosMetodologiaPara aulasTérminos de UsoPolítica de PrivacidadPolítica de CookiesDescargo de Responsabilidad

Soporte

Contacto SoporteFAQKit para desarrolladoresDocumentación MCP

Sociales

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Reservados todos los derechos.
Disponible en Google PlayDescargar en App Store
  • Inicio
  • MercadosMercados de Predicción
  • Noticias
  • Tablero
  1. Mercados de Predicción
  2. Health & Medicine
  3. Phase 3 Result: Sublingual Minoxidil by Samson Clinical Operations (June 2026)
Phase 3 Result: Sublingual Minoxidil by Samson Clinical Operations (June 2026)

Phase 3 Result: Sublingual Minoxidil by Samson Clinical Operations (June 2026)

1.0% (24h)One-OffHealth & MedicineCiencia12d
KalshiKalshiComprobar disponibilidadKYC requerido2% de comisión
Probabilidad implícita actual
Success
Success 17%-1.0%
Líder entre 5 opciones
Calidad del mercado

28 / 100

Baja calidad
Volumen 24h

1 €

Liquidez

5,4 €

Baja liquidez
Compra / Venta

16.0% / 23.0%

Spread

43.8%

Spread amplio
Datos de mercado

Actualizado hace 3 minutos

10 jun 26, 0:001 jul 26, 3:59

Tendencias

Resultado24hProbabilidad

Resultado elegido

Success17%

Reglas

If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Success results in June 2026, the market resolves to Yes.

Kalshi
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Mixed results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Failure results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Ambiguous results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports No Results results in June 2026, the market resolves to Yes.

Mercados Relacionados

Manifold Markets

Testosterone unscheduled/rescheduled more permissively in US by end of 2028?

994,6 €
Sí: 22.2%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Delivery Ritalin exists in one year?

432,8 €
Sí: 7.5%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Will there be a cure for schizophrenia before 2032?

432,8 €
Sí: 11.8%Manifold MarketsMANIFOLD MARKETS
When will Beam Therapeutics submit a BLA for Risto-cel?

When will Beam Therapeutics submit a BLA for Risto-cel?

0,9 €
before December: 54%KalshiKALSHI
When will Compass Pathways submit a NDA for COMP360 psilocybin?

When will Compass Pathways submit a NDA for COMP360 psilocybin?

0,1 €
before October: 42%KalshiKALSHI
When will Intellia Therapeutics submit a BLA for Lonvo-z?

When will Intellia Therapeutics submit a BLA for Lonvo-z?

0 €
before September: 46%KalshiKALSHI

Activos en estos temas

BitcoinBTC$63,931.19-2.89%EthereumETH$1,734.84-3.27%SolanaSOL$71.19-3.46%DogecoinDOGE$0.0847-3.23%XRPXRP$1.17-3.56%BNBBNB$592.24-2.19%

Noticias Relacionadas

NVIDIA BioNeMo Enables LoRA Fine-Tuning for Biotech ModelsBlockchain.NewsEthereum Researcher: Quantum-Proof Accounts Possible for $0.07Blockchain.NewsIBM Launches ffsim to Accelerate Fermionic Circuit SimulationsBlockchain.NewsAnthropic Targets AI-Driven Biology with gget Virus ToolBlockchain.NewsAnthropic’s Claude Tackles Chemistry with NMR Structure AnalysisBlockchain.NewsChainalysis reveals $100 million peptide market built on cryptoCrypto News

Reglas

If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Success results in June 2026, the market resolves to Yes.

Kalshi
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Mixed results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Failure results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Ambiguous results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports No Results results in June 2026, the market resolves to Yes.